TIB-161 HuT 78 人T**細(xì)胞白血病細(xì)胞
ATCC® Number: TIB-161?
Designations: HuT 78
Depositors: AF Gazdar
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens (human)
Morphology: lymphoblast
Source: Disease: Sezary Syndrome
Cell Type: cutaneous T lymphocyte;
Cellular Products: interleukin 2 [1140]
tumor necrosis factor alpha (TNF alpha) [23420]
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications: transfection host (Nucleofection technology from Lonza)
Receptors: interleukin 2 (IL-2), expressed [1140]
Tumorigenic: Yes
Antigen Expression: CD4; Homo sapiens [22610]
DNA Profile (STR): Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 8,12
D16S539: 11,12
D5S818: 11,12
D7S820: 8,11
THO1: 8,9
TPOX: 8,9
vWA: 14,15
Age: 53 years a
Gender: male
Ethnicity: Caucasian
Comments: H9 (ATCC HTB-176) is a clonal derivative of HuT 78 [Pubmed: 2567177].
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 2 X 10 exp5 viable cells/ml. Maintain cultures at cell concentrations between 5 X 10 exp4 and 8 X 10 exp5 viable cells/ml. maintain cell density at less than 1 X 10 exp6 cells/ml.
Medium Renewal: Two to three times weekly
Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Doubling Time: about 65 hours
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
derivative:ATCC HTB-176
References: 1140: Gootenberg JE, et al. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J. Exp. Med. 154: 1403-1418, 1981. PubMed: 6975346
22484: Mann DL, et al. Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Res. Hum. Retroviruses 5: 253-255, 1989. PubMed: 2567177
22610: Gazdar AF, et al. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 55: 409-417, 1980. PubMed: 6244013
23228: Chen TR. Karyotypic derivation of H9 cell line expressing human immunodeficiency virus susceptibility. J. Natl. Cancer Inst. 84: 1922-1926, 1992. PubMed: 1460674
23420: O'Connell MA, et al. Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78. J. Biol. Chem. 270: 7399-7404, 1995. PubMed: 7706285
32283: Hu SX, et al. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res. 57: 3339-3343, 1997. PubMed: 9269991
32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128
32796: Bloom TJ, Beavo JA. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93: 14188-14192, 1996. PubMed: 8943082
